Relationship between Day 0 dosimetric parameters and biochemical relapse-free survival in patients treated with transperineal permanent prostate interstitial brachytherapy with 125I seeds

被引:2
|
作者
Garran, Cristina [1 ]
Ciervide, Raquel [1 ]
Cambeiro, Mauricio [1 ]
Moreno-Jimenez, Marta [1 ]
Ramos, Luis I. [1 ]
Martinez-Monge, Rafael [1 ]
机构
[1] Univ Navarra, Univ Navarra Clin, Dept Oncol, Div Radiat Oncol, E-31080 Pamplona, Navarre, Spain
关键词
Brachytherapy; Prostate cancer; I-125; Monotherapy; Implant quality; Quantifiers; D-90; V-100 (%); CANCER; RECOMMENDATIONS; RADIOTHERAPY; IMPLANTATION; THERAPY; FAILURE; PD-103; IMPACT; EDEMA;
D O I
10.1016/j.brachy.2009.04.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
OBJECTIVES: To determine the relationship between dosimetric parameters obtained on postimplantation Day 0 and biochemical relapse-free survival (bRFS) in patients treated with I-125 transperineal interstitial permanent prostate brachytherapy (TIPPB). METHODS: Two-hundred twenty men with low-risk (n = 155, 70.4%), low-volume intermediate-risk (n = 63, 28.7%), or high-risk (n = 2, 0.9%) prostate cancer were treated with TIPPB between December 2000 and June 2006. Seventy-four (33.6%) patients received short-term (3-6 months) androgen suppression therapy before TIPPB. The median followup for patients free of biochemical failure was of 37.9 months (range, 24.0-84.5 months). RESULTS: The receiver operating characteristic (ROC) analysis established a best-fit cutoff value for the quantifiers D-90 and V-100 of 147 Gy and 92%, respectively. The Kaplan-Meier analysis of bRFS at the cutoff value of D-90 = 147 Gy using the ASTRO, nadir + 2, and combined (ASTRO and nadir + 2) definitions showed a trend toward statistical significance for the ASTRO (p = 0.076) and nadir + 2 (p = 0.064) definitions and a statistically significant correlation for the combined definition (p = 0.033). The corresponding 7-year bRFS for the D-90 > 147 Gy and D-90 <= 147 Gy subsets using the ASTRO, nadir + 2, and combined definitions were 96.5% vs. 89.7% (ASTRO, p = 0.076); 93.7% vs. 70.5% (nadir + 2, p = 0.064); and 94.4 vs. 75.5% (combined, p = 0.033). The V-100 (%) cutoff value of 92% predicted by the ROC analysis was not significant. Among other cutoff values, only D-90 = 140 Gy (p = 0.050) and D-90 = 160 Gy (p = 0.098) showed a trend toward statistical significance when the nadir + 2 and the ASTRO definitions were used. The rest of dosimetric, tumor, and patient parameters did not show statistical correlation with bRFS in the Kaplan-Meier analysis. CONCLUSIONS: The cutoff value of D-90 = 147 Gy obtained on postimplantation Day 0 showed a trend toward significant correlation with bRFS when the standard ASTRO and nadir + 2 definitions were used and a weak but statistically significant correlation with bRFS as per the nonstandard combined definition in a series of patients with predominantly low-risk disease (70.4%) treated at high radiation doses (median D-90 = 152.9 Gy, median V-100 = 92.5%). (C) 2010 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:8 / 14
页数:7
相关论文
共 27 条
  • [21] Population-based Study of Biochemical and Survival Outcomes After Permanent 125I Brachytherapy for Low- and Intermediate-risk Prostate Cancer
    Morris, W. J.
    Keyes, M.
    Palma, D.
    Spadinger, I.
    McKenzie, M. R.
    Agranovich, A.
    Pickles, T.
    Liu, M.
    Kwan, W.
    Wu, J.
    Berthelet, E.
    Pai, H.
    UROLOGY, 2009, 73 (04) : 860 - 865
  • [22] Eligibility criteria according to EAU/ESTRO/SIOG guidelines for exclusive iodine-125 brachytherapy for intermediate-risk prostate adenocarcinoma patients: impact on relapse-free survival
    Robin, Sophie
    Chabaud, Sylvie
    Serre, Anne-Agathe
    Bringeon, Beatrice
    Clippe, Sebastien
    Rocher, Francois
    Desmettre, Olivier
    Bringeon, Gabriel
    Gassa, Frederic
    Pommier, Pascal
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2021, 13 (04) : 373 - 386
  • [23] Comparison between preoperative and real-time intraoperative planning 125I permanent prostate brachytherapy: long-term clinical biochemical outcome
    Haim Matzkin
    Juza Chen
    Larissa German
    Nicola J Mabjeesh
    Radiation Oncology, 8
  • [24] Global survival and biochemical relapse-free survival in patients with prostate cancer treated with intensity modulated radiotherapy (IMRT) at the National Cancer Institute
    Jimenez Cotes, Adriana
    Alejandro Esguerra, Jose
    Morales-Ramirez, Laura
    Norena, Paulina
    Ballesteros, Holman
    Isabel Cotes, Martha
    Gonzales, Garvin
    Rugeles, Jorge
    Manuel Hoyos, Luis
    Ospino-Pena, Rosalba
    REVISTA COLOMBIANA DE CANCEROLOGIA, 2020, 24 (04): : 157 - 163
  • [25] A retrospective analysis after low-dose-rate prostate brachytherapy with permanent 125I seed implant: clinical and dosimetric results in 70 patients
    Chiumento, Costanza
    Montagna, Antonietta
    Clemente, Stefania
    Cozzolino, Mariella
    Fusco, Vincenzo
    TUMORI JOURNAL, 2011, 97 (03): : 335 - 340
  • [26] Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: The combined experience of nine institutions in patients treated in 1994 and 1995
    Kupelian, P
    Kuban, D
    Thames, H
    Levy, L
    Horwitz, E
    Martinez, A
    Michalski, J
    Pisansky, T
    Sandler, H
    Shipley, W
    Zelefsky, M
    Zietman, A
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 61 (02): : 415 - 419
  • [27] Clinical and dosimetric analysis of 469 prostate cancer patients treated in France in 2005 by permanent implant brachytherapy using the Iodin 125 seeds IsoSeed Bebig:: report to the French Economic committee of health products (CEPS)
    Cosset, J. -M.
    Gomme, S.
    Peiffert, D.
    Guerif, S.
    Labib, A.
    Hannoun-Levi, J. -M.
    Martin, P.
    Quetin, P.
    Nguyen, T. -D.
    Flam, T.
    Thiounn, N.
    Henni, M.
    Rosenwald, J. -C.
    Housset, M.
    Pontvert, D.
    Asselain, B.
    Chauveinc, L.
    CANCER RADIOTHERAPIE, 2007, 11 (04): : 206 - 213